# Hyperliquid Strategies Inc (PURR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.18, market value $2.4 billion.

## Valuation
- **P/E (trailing): 3.8×** (5-yr avg 2.5×, 3-yr avg 2.5×). Hyperliquid Strategies Inc trades at 3.8× trailing earnings, well above its own five-year average of 2.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 41.3×, higher than trailing, so analysts expect earnings to fall.
- **Price / sales: 254.7×**. Each dollar of revenue is priced at 254.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 26.4%**. The inverse of the P/E: 26.4% of the price is earned each year.

## Profitability
- **Return on equity: 16.3%**. 16.3% on shareholders' equity is solid.
- **Return on assets: 14.8%**. Each dollar of assets produces 14.8% of profit.

## Financial health
- **Current ratio: 41.62** (quick 41.62). Current assets cover the next year's liabilities 41.62 times.
- **Altman Z-score: 9.89**. A Z-score of 9.89 places the company in the safe zone for bankruptcy risk.

## Dividends
- **Dividend: none**. Hyperliquid Strategies Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Hyperliquid Strategies Inc; the consensus is strong_buy, with an average price target of $19.87 (+63% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -13.9%** (304.7% above the low). Trading 14% below its 52-week high.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 3.43** (volatility 107%). Beta of 3.43 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PURR · Page: https://foliofundamentals.com/stocks/purr

Not investment advice.